Peptides Studied for Libido & Sexual Health

Sexual-health peptides work on the brain rather than the plumbing. Desire and arousal run through the melanocortin pathways (bremelanotide's target), the kisspeptin cascade that switches on the reproductive-hormone system, and the oxytocin system tied to bonding and arousal. That's what separates this research from the well-known blood-flow medicines: it studies the desire and signaling side.

This is also the pillar with the sharpest approved-versus-research line. One member — bremelanotide — is FDA-approved for low sexual desire in premenopausal women. The rest are research-stage, and one of them (melanotan II) is unapproved, with documented side effects and regulatory warnings around its tanning use.

How They Compare

Bremelanotide is the anchor: derived from melanotan II's research but refined, it's FDA-approved (as Vyleesi) for hypoactive sexual desire disorder — taken as needed before sexual activity, not daily. Kisspeptin works further upstream, triggering the GnRH cascade that governs LH, FSH, and sex-hormone output; UK human trials have studied it for low desire and fertility, though it remains investigational.

Oxytocin is approved only for labor induction — its social-bonding and arousal research comes from smaller human and animal studies. Melanotan II carries the honest caveats: its sexual-function findings sit alongside documented nausea, involuntary erections, and tanning-safety warnings, and it remains unapproved. Nothing here is dosing guidance; each member's guide carries the sourced studies.